JUNS JUPITER NEUROSCIENCES, INC.

Price Chart

Executive Summary

Jupiter Neurosciences has priced a registered direct offering of 7,142,858 shares of common stock at $0.28 per share, raising gross proceeds of $2 million. The offering is priced at a ~36.6% premium to the last closing price of $0.2050, but the net proceeds of ~$1.685M provide only modest working capital runway for a clinical-stage biotech with a going concern qualification. The company also disclosed a non-binding term sheet for a potential licensing deal with PharmAla Biotech involving a $3.33M upfront consideration and $600K escrow deposit, adding another layer of execution risk and cash drain.

Actionable Insight

Key Facts

• Offering 7,142,858 shares at $0.28/share for gross proceeds of $2,000,000.24
• Net proceeds of ~$1.685M after placement agent fees of $140,000 and estimated offering expenses of $175,000
• Offering price is a 36.6% premium to the $0.2050 last sale price on May 20, 2026
• Pro forma shares outstanding increase to 43,424,110 from 36,281,252 — 19.7% dilution
• As of March 31, 2026, net tangible book value was negative $(0.08)/share; after offering improves to negative $(0.03)/share
• Dilution to new investors of $0.31/share relative to offering price
• Existing auditor's report includes going concern explanatory paragraph for FY2025 and FY2024
• Company has approximately $6.0M in convertible notes outstanding from Yorkville (Oct/Dec 2025), convertible at $1.50/share with 8% interest (18% default)
• Non-binding term sheet signed May 19, 2026 to acquire U.S. rights to PharmAla's ALA-002 for $3.33M upfront ($1.5M cash + $1.83M equity) plus milestones and 3% royalty; $600K placed in escrow
• 30-day lock-up on further equity issuance; 1-year prohibition on variable rate transactions

Financial Impact

Immediate dilution of ~19.7% to existing shareholders; net proceeds of $1.685M represent less than 5 quarters of cash burn for a clinical-stage company with no meaningful product revenue and $6M in convertible notes due Oct 2026

Risk Factors

• Going concern qualification in audited financials — negative tangible book value persists post-offering
• Insufficient capital to fund Phase IIa Parkinson's trial and PharmAla license simultaneously
• Yorkville convertible notes ($6M principal, 8% interest, mature Oct 2026) are deep underwater at current stock price, creating massive dilution if converted or forcing cash repayment
• PharmAla term sheet is non-binding with 90-day exclusivity — $600K escrow at risk if deal fails
• At $7M market cap, low liquidity and penny stock risk if Nasdaq listing requirements not met

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status

Related Tickers